Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Immunogenicity and Revaccination of Shingrix in Renal Transplant Recipients
NCT04176939Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2019
- Primary completion
- Aug 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of herpes zoster vaccine (recombinant, adjuvanted) in herpes zoster (HZ), sponsored by GSK. Primary endpoints: Anti-glycoprotein E (Anti-gE) Antibody Concentrations, as Assessed in the Long Term Follow-up (LTFU) Phase at Month 24 and Anti-gE Antibody Concentrations, as Assessed in the Revaccination Active Phase at Month 26. Started Dec 2019; status: completed.
02
Drugs
herpes zoster vaccine (recombinant, adjuvanted)
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT04176939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04176939.